Stockreport

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

OS Therapies Incorporated  (OSTX) 
PDF Dialogue open with FDA in preparation for End of Phase 2 Meeting requestNew canine elite responder biomarkers added to human biomarker strategy NEW YORK--(BUSINESS WI [Read more]